Zentalis Pharmaceuticals, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
Business Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, CA, 92121
Mailing Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, CA, 92121
Phone
(858) 263-4333
Fiscal Year End
1231
EIN
823607803
Financial Overview
FY2025
-$137.06M
Net Income
$337.19M
Stockholders' Equity
$35.99M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 26, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 10, 2026 | View on SEC |
| 4 Insider stock transaction report | February 10, 2026 | View on SEC |
| 4 Insider stock transaction report | February 10, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
| 8-K Current report of material events | January 9, 2026 | View on SEC |
| 4 Insider stock transaction report | January 9, 2026 | View on SEC |
| 4 Insider stock transaction report | January 9, 2026 | View on SEC |
Annual Reports
10-K
March 26, 2026
- Lead drug candidate azenosertib (ZN-c3) shows promise for platinum-resistant ovarian cancer.
- Company regained 100% of rights to azenosertib, maximizing potential future profits.
Insider Trading
STRONG SELL
5 insiders
11 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.